A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability
of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid
neoplasms.